Gemma Frisius Fund
VC Fund
Leuven, Belgium
Gemma Frisius Fund is a VC fund in Leuven focused on Biotechnology and Medical. On July 3, 2002 the Gemma Frisius Fund II was established. Continuing the work of its predecessor Gemma Frisius Fund I, this is a venture capital fund providing seed capital and start-up capital to spin-off companies intending to commercialize knowledge and research developed at K.U.Leuven. Following the success of the first edition of the Fund,the three partners - Fortis Private Equity, KBC Investco and K.U.Leuven Research & Development - unanimously decided to extend this unique form of cooperation between the academic and financial worlds.The Gemma Frisius Fund I invested in 15 projects, for a total value of 8 million eur. The fund still has 4.4 million eur available for follow-up investment in these projects. The new fund will not invest in companies belonging to the portfolio of the first edition of the fund. The management structure of the Gemma Frisius Fund II will remain the same. The projects are analyzed in an advisory committee and presented for approval to the board of directors. Two directors from each partner are represented on the board.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Gemma Frisius Fund invests in
Stages Gemma Frisius Fund invests in
Countries Gemma Frisius Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $634k–$4.6M
- Series A
- $932k–$84M
- Series B
- $4.7M–$24M
Investment Focus
Industry
- Biotechnology 13 (33%)
- Medical 6 (15%)
- Health Care 6 (15%)
- Software 5 (13%)
- Therapeutics 4 (10%)
Stage
- Seed 12 (30%)
- Series A 8 (20%)
- Series B 8 (20%)
- Funding Round 4 (10%)
- Venture - Series Unknown 2 (5%)
Country
- Belgium 27 (68%)
- France 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Paul Van Dun
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Rudi Cuyvers
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Optiflux is an innovative device that automates the entire fresh fruit storage management process. Optiflux's expertise combines fruit physiology knowledge with cutting-edge technology. | $2.9M / Seed / Jul 09, 2026 | ||
| Runeasi is revolutionizing the measurement and interpretation of lab-grade biomechanical data. It is measuring biomechanics from just one device placed on the pelvis and is supporting a suite of use cases from walking and running to sprinting. This is enabling health and performance professionals to make better decisions when assessing andaddressing sports injuries. Ultimately, this is improving the recovery, health, and well-being of recreational and elite sports(wo)men around the world. | $1.2M / Seed / Feb 04, 2026 | ||
| Aspect Analytics offers consultancy services, home-grown software, development of workflows, and customization of software. | $11.7M / Series A / Sep 09, 2025 | ||
| Magics Technologies is a nuclear research center that develops autonomous machines for sustainable energy sources. | $11.1M / Venture - Series Unknown / Apr 16, 2025 | ||
| Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | ||
| Tavira Therapeutics develops an advanced platform that enhances gene delivery of AAV (adeno-associated virus). The company's approach is to equip AAV vectors with specific molecules that allow for more targeted and safer gene therapies, representing a significant advancement in the field. Founded as a spin-off from KU Leuven and Trellis,Tavira is leveraging groundbreaking research to develop modular AAV capsid technologies to improve gene therapy treatments. | $1.1M / Pre-Seed / Oct 01, 2024 | ||
| Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M / Series A / Jun 26, 2024 | ||
Protealis
|
Sustainable plant proteins for Europe | $23.9M / Series B / Jan 23, 2024 | |
| Effex provides a cloud-based software solution that streamlines physical testing processes, making them more efficient and sustainable. Effex presents a solution for businesses and research institutions seeking to revolutionize their experimental processes. With a focus on efficiency, collaboration, cost-effectiveness, and expertise-driveninnovation, Effex offers a suite of features that make it the top choice for experimental planning and data analysis. | $1.7M / Seed / Jul 01, 2023 | ||
| DName-iT is a genetic analysis tool that offers DNA-based barcode labeling technology and a software platform that can ensure reliable, cost-effective NGS specimen identification. | $634K / Seed / Jun 30, 2023 | ||
| See all 40 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gemma Frisius Fund invest in?
Gemma Frisius Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 40 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Gemma Frisius Fund's check size?
Gemma Frisius Fund typically joins rounds of $634k–$4.6M at Seed, $932k–$84M at Series A and $4.7M–$24M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gemma Frisius Fund participates in.
How do I contact Gemma Frisius Fund?
Public channels for Gemma Frisius Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Gemma Frisius Fund?
The team at Gemma Frisius Fund includes Paul Van Dun (Managing Director) and Rudi Cuyvers (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
